Create your personal agenda –check the favourite icon
Keynote panel: Tackling future viral pandemics – a holistic view
Keynotes
- Use of antiviral drugs to reduce morbidity and mortality
- Global-preparedness programmes that potentiate
- ability to rapidly test existing and newly designed antiviral drugs (small molecule and neutralizing mAbs)
- development of safe, effective, easy-to-produce, reasonably priced vaccines
- Speed of research to serve as a template for future viral pandemics
Keynote presentation: Epidemiological surveillance to inform global preparedness and response
Keynotes
- How are viral, ecological, and environmental factors used to determine which viruses pose the greatest threat to human health?
- Understanding the virus-host ecology of emerging viruses
- Drivers of zoonotic and cross-species transmission
Keynote panel: Pan-coronavirus vaccines – feasibility & funding
Keynotes
- Renewed interest in the development of pan-coronavirus vaccines
- Implications for the next pandemic - baseline levels of cross-reactivity to lower clinical severity & prevent hospitalisations – how much is enough protection?
- Multiple targets
- Structural vaccinology & other approaches
- Cost of manufacture? Is developing the nanoparticle-based vaccine same cost as allum-based vaccines?
Additional panellists TBC
Exhibition & Partnering Break
Keynotes
Tea, Coffee and Refreshments served in the exhibition areaOne-to-one networking meetings
Socially Distanced Roundtables
Keynotes
Interactive discussions with like-minded peers tackling the similar challenges in vaccine, antibody and immunotherapy development. Max 20 per table. Sign-up in advance.
- AMR – Trial site selection – Speaker TBC
- Emergent Biosolutions – Increasing consumer acceptance of travel vaccine recommendations - Speaker TBC
First Multitope COVID-19 vaccine, from mice to man
Infectious Disease Vaccines
Enhancing anti-PD-1 immune responses in solid tumors
Cancer Immunotherapy
Accelerating therapeutics & biomarker discovery through single-cell proteomics - Title TBC
Immune Profiling & Translational Science
Senior Representative, IsoPlexis
COVID-19 & Influenza vaccine development using MIMIX platform
Infectious Disease Vaccines
Clinical updates in the development of an oral COVID-19 vaccine candidate
Infectious Disease Vaccines
Discovery & development of antibodies to relieve immunosuppression in the tumor microenvironment
Cancer Immunotherapy
Systems vaccinology enabled by multiomic single cell immune profiling
Immune Profiling & Translational Science
Senior Representative, 10X Genomics
xMAP platform technology combining low- and high-plex capabilities - Title TBC
Immune Profiling & Translational Science
Senior Representative, Luminex
CORAL COVID-19 Vaccine – inducing immunity against spike & other viral antigens
Infectious Disease Vaccines
Panel – TCRs from discovery to therapeutics
Cancer Immunotherapy
Additional panellists TBC
Panel: What does the future look like for the development, validation & execution of biomarkers for response, resistance & disease monitoring
Immune Profiling & Translational Science
- How can we improve early cancer screening? What is early – stage 1? Or stage 1-3?
- Difference between screening and detection?
- Alternative biomarker sources - Exosomes / microbiome-based / ADCs
- Challenges and opportunities in novel biomarker sources
- Extraction challenges
- Reimbursement issues (companion Dx vs early detection not reimbursed)
- Multi-cancer detection? A valuable proposition?
Additional panellists TBC
Evaluation of covid-19 vaccines with saponin vaccine adjuvant TQL1055
Infectious Disease Vaccines
Senior Representative, Adjuvance Technologies
VLP-based COVID-19 vaccine development
Infectious Disease Vaccines
Animal Study Reproducibility: Problems and Solutions -15min
Infectious Disease Vaccines
Using Dengue fever to treat cancer
Cancer Immunotherapy
Microbiome driven liquid biopsy for early cancer detection
Immune Profiling & Translational Science
The impact of COVID vaccine work on research sites and the future of this from a site’s perspective
Infectious Disease Vaccines
Ensuring supply during decentralized vaccine trials
Infectious Disease Vaccines
Senior Representative, Marken
Personalised oncolytic adenovirus therapies
Cancer Immunotherapy
Senior Representative, Virica
Panel: Overcoming T-cdell exhaustion in infection and cancer
Immune Profiling & Translational Science
Additional panellists TBC
Critical role of protein reagents in vaccine development
Infectious Disease Vaccines
Oncolytic viruses mechanism of action and interaction with immunomodulatory agents
Cancer Immunotherapy
Create your personal agenda –check the favourite icon
Keynote panel: Moving liquid biopsies into the clinic
Keynotes
- Are we moving more towards blood-based approaches over tissue-based approaches? What have been the challenges with this?
- What is the best use of ctDNA? Selection? Monitoring? Early detection?
- Future applications
- Key issues and gaps in technology – what are the best types of technology? Personalised? General?
- Is this technology ready for implementation? -
- Clinical trial methodologies and logistics for integrating liquid biopsies into clinical workflow
- What should be done with positive readings for early detection?
Carlos Bais, Senior Director, Oncology Biomarker Development, Genenetch Inc
Keynote panels & Interviews: Raising capital – has the pandemic reignited interest in vaccine & immunotherapy biotechs?
Keynotes
- What has been the experience of both investors and vaccine & immunotherapy biotechs in raising capital during the pandemic?
- Will interest be sustained? What are the advantages and disadvantages of renewed interest?
- Will success of mRNA inspire confidence in other vaccine & immunotherapy modalities & platforms?
Additional panellists TBC
Chair’s opening remarks
Cancer Immunotherapy
Broad-spectrum pneumococcal conjugate vaccine development
Infectious Disease Vaccines
Panel: Are neoantigens living up to their initial promise? What questions remain unanswered?
Cancer Immunotherapy
- Addressing ongoing challenges in NeoAg identification / verification
- Some NeoAgs more immunogenic than others – what role do different platform technologies play?
- What elements of the immune cycle should we look more closely at/ need to be addressed?
- Rational combination with other IO?
- Evidence for inhibitory antigens and their role?
Novel T-cell tests for the early detection of infectious disease & cancer
Immune Profiling & Translational Science
Senior Representative, Adaptive Biotechnologies
Challenges and opportunities in developing next generation PCVs
Infectious Disease Vaccines
- Optimal vaccine formulation, limitations of conventional chemistry and vaccination schedule for different settings and high-risk populations
- Impact of serotype replacement following PCV use
- Transmission in high-burden settings
- Carrier suppression - understanding the immunological markers of long-term protection against carriage
Additional panellists TBC
Krishna Prasad, Founder, Citranvi Biosciences LLC
RT-qPCR, sequencing, and T cell immunity testing supporting SARS-CoV-2 vaccine clinical trials
Immune Profiling & Translational Science
Senior Representative, Eurofins Viracor
In depth functional characterization of novel monoclonal antibodies to the SARS-CoV2 virus
Immune Profiling & Translational Science
Extrapolation of epitope prediction from IO onto infectious diseases: lessons learned
Cancer Immunotherapy
Development of a novel assay to assess the avidity of dengue virus-specific antibodies elicited in response to a tetravalent dengue vaccine
Immune Profiling & Translational Science
David Dominguez, Research Associate, Takeda
SARS-CoV-2 Immunity: What have we learnt about characteristics of the immune response to Covid-19 infection pre & post vaccination?
Immune Profiling & Translational Science
- Adaptive responses to in natural infection and vaccination
- Durability of those responses
- Adaptive responses to variants
- Pan coronavirus responses addressed experimentally
Additional panellists TBC
High-throughput antibody production for vaccine & immunotherapy R&D
Infectious Disease Vaccines
Senior Representative, SinoBiological
Scalable, host independent, continuous flow mRNA vaccine manufacturing
Infectious Disease Vaccines
Tailoring vaccine manufacturing strategies to multiple platforms
Infectious Disease Vaccines
Senior Representative, Sartorius Stedim Biotech
Development of eVLP platform for viral associated cancers
Cancer Immunotherapy
Senior Representative, VBI Vaccines
SARS-CoV-2 Assay development
Immune Profiling & Translational Science
Senior Representative, Luminex
Avoiding bottlenecks and scale-up of viral vaccines
Infectious Disease Vaccines
Combining real-time impedance monitoring and live cell imaging to rapidly identify and characterize antiviral drugs and neutralizing antibodies
Immune Profiling & Translational Science
Use of needle-free injection technology in vaccine delivery
Infectious Disease Vaccines
Hapentized vaccines for viral diseases & cancer
Cancer Immunotherapy
Viral vector characterization - Title TBC
Immune Profiling & Translational Science
Patch technology for vaccine delivery
Infectious Disease Vaccines
Use of patch technology for influenza vaccines
Infectious Disease Vaccines
Create your personal agenda –check the favourite icon
Keynote Panel: How has our understanding of resistance in oncology evolved?
Keynotes
- How do we think of resistance phenotypes?
- What are the major mechanisms of resistance?
Additional panellists TBC
Keynote panel: US Immunization Policy – what have we learnt that could better prepare us for the next public health crisis
Keynotes
- How can we improve access in the USA?
- Preparedness for mass immunizations & follow through – is USA ready for future pandemics & general adult vaccines?
- Maintaining immunization registries
- Payment structure for seniors – out of pocket costs / Medicare part B&D
- IP issues? Will this set a president? - Topic TBC based on current events
- Challenges in converting immunization policy recommendations into legislation
- What were the economic implications of the pandemic as a whole – what was the cost of illness?
- What have we learned from vaccine programs about improving uptake and bolster confidence?
- How do we build a more resilient public health infrastructure?
Emerging exosome-based vaccine platform – targeting infectious diseases and cancer
Cancer Immunotherapy
Live attenuated recombinant vaccines for RSV and COVID-19
Infectious Disease Vaccines
Safety surveillance cohort studies of vaccinia vaccine among military personnel
Infectious Disease Vaccines
Senior Representative, Emergent Biosolutions
Development of Lassa, CHIKV & MERS CoV vaccines using measles viral vector platform
Infectious Disease Vaccines
Design and evaluation of vaccines against hemorrhagic fevers using the MVA-VLP platform
Infectious Disease Vaccines
last published: 07/Oct/21 09:45 GMT
Password must meet the following requirements:
- At least one letter
- At least one capital letter
- At least one number
- Be at least 6 characters
Dr James Crowe, Director,
Vanderbilt Vaccine Center
Dr. James Crowe is Director of the Vanderbilt Vaccine Center and the Ann Scott Carell Professor of Pediatrics, Pathology, Microbiology and Immunology at Vanderbilt. His laboratory studies the human immune response to infection for a wide variety of major human pathogens, including many emerging...
Dr Tomas Cihlar, Vice President, Virology,
Gilead Sciences, Inc.
Tomas Cihlar, PhD is a Vice President of Virology at Gilead Sciences with responsibility for coordinating preclinical antiviral research. He joined Gilead after receiving his PhD in Biochemistry from the Institute of Organic Chemistry and Biochemistry in Prague, Czech Republic. While at Gilead, he...
Jacqueline Miller, Senior Vice President, Therapeutic Area Head, Infectious Disease,
Moderna Therapeutics
Dr. Jacqueline Miller is currently the Therapeutic Area Head for Infectious Diseases at Moderna, and leads the Development teams for Vaccines. She received her M.D. from Northwestern University and trained in pediatrics at Children's Hospital of Philadelphia. She later joined Merck Research...
Vincent Munster, Chief of Virus Ecology Unit,
NIAID, NIH
Dr. Vincent Munster received his Ph.D. in virology from Erasmus University, Rotterdam, the Netherlands, in 2006. During his Ph.D. studies, Dr. Munster studied the ecology, evolution, and pathogenesis of avian influenza viruses. He continued his training at the Erasmus Medical Center from 2006 to...
Maria Elena Bottazzi, Co-Director, Texas Children’s Hospital Center for Vaccine Development,
Baylor College of Medicine
Maria Elena Bottazzi, PhD is the Associate Dean of the National School of Tropical Medicine, Professor of Pediatrics and Co-director of Texas Children's Hospital Center for Vaccine Development at Baylor College of Medicine in Houston, Texas. She is an internationally-recognized...
Mark Newman, CSO,
GeoVax, Inc.
Dr. Newman has more than 30 years’ experience in the biotechnology sector serving in senior management roles at GeoVax (Atlanta, GA), PaxVax (San Diego, CA), Pharmexa (Horsholm, Denmark), Epimmune (San Diego, CA), Vaxcel (Atlanta, GA), Apollon (Philadelphia, PA) and Cambridge Biotech (Boston, MA)...
Prof. Pamela Bjorkman, David Baltimore Professor of Biology and Biological Engineering,
California Institute of Technology
Dr. Bjorkman is the David Baltimore Professor of Biology and Biological Engineering and a Merkin Institute Professor at Caltech. She received a BA in Chemistry from the University of Oregon and a PhD in Biochemistry from Harvard. As a graduate student and postdoctoral fellow with Don Wiley, she...
Dr Dennis Burton, Co-chair Department of Immunology and Microbiology,
The Scripps Research Institute
Dennis Burton is the Co-Chair and Professor in the Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, USA. He was recently awarded the James and Jessie Minor Chair in Immunology. He received his B.A. in Chemistry from Oxford University and his Ph.D from Lund...
Dr Farshad Guirakhoo, CSO,
Vaxxinity
Farshad was named in 2014 as no. 22 in the list of The Most Influential People in Vaccines . Dr. Guirakhoo is the co-inventor of the ChimeriVaxTM-technology platform, the world?s first recombinant viral vector platform that was approved for any human vaccine. This platform has been successfully...
David Canton, Senior Director, R&D And Clinical Science,
OncoSec Medical
David received his PhD in Biochemistry from Western University (Ontario Canada) where he studied the regulation of protein kinase CK2 through spatial targeting by interaction partners. His interest in kinase signaling led him to Dr. John Scott?s laboratory at the University of Washington, where he ...
Ted Hibben, CBO,
Vaxess
Over the course of his career, Ted has devised and executed on business development and corporate strategy at multiple early-stage biotherapeutic companies as a member of senior leadership. In addition to fundraising roles, he has formed over $3 billion in platform and product R&D...
Dr Sean Tucker, Chief Scientific Officer And Vice President Research,
Vaxart
Dr. Tucker completed his doctoral degree in Immunology at the University of Washington. Dr. Tucker is the Chief Scientific Officer and Vice President for Research at Vaxart, Inc, a company focused on mucosal vaccine delivery. He has published several papers in immunology and served as a grant...
Kamal Puri, CSO,
OncoResponse, Inc.
Dr. Puri received his PhD from Indian Institute of Science, Bangalore, India. During his research period, he was a Research Fellow of the Council of Scientific and Industrial Research, India. Dr. Puri undertook his immunology training with Timothy A. Springer, PhD Latham Family Professor at the...
Dr Rea Dabelic, Manager, Immunology Segment Marketing,
10x genomics
Rea earned her undergraduate and PhD degrees in Microbiology and Immunology from the University of Florida, where she studied interferon signaling and developed antiviral therapeutics. She completed her postdoc in Virology at Columbia University where she studied viral immune evasion and host...
Karin Jooss, CSO,
Gritstone Oncology
Karin Jooss serves as Chief Scientific Officer of Gritstone Oncology. Dr. Jooss joined Gritstone from Pfizer, where she served as head of Cancer Immunotherapeutics within the Vaccine Immunotherapeutics department for seven years. While at Pfizer, she built and led immuno-oncology teams, was a...
Dr Hanspeter Gerber, CSO,
3T Biosciences
Hans-Peter has over 20 years of research and development experience in oncology, including antibody-drug conjugates (ADCs), redirected T-cell targeting compounds and adoptive T-cell therapies. He has been leading Pfizer?s Bioconjugates division as CSO, overseeing Pfizer's efforts in ADC...
Sharon Benzeno, Chief Business Development Officer,
Adaptive Biotechnologies
Dr. Sharon Benzeno is the Chief Business Development Officer and leads the Drug Discovery group of Adaptive Biotechnologies, a commercial-stage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. Prior to joining...
Stephen Schoenberger, Professor,
La Jolla Institute for Allergy and Immunology
Dr. Schoenberger joined LIAI in 1998 as an Assistant Professor in the Division of Immune Regulation. In 2002, Dr. Schoenberger became an Associate Professor in the Division of Cellular Immunology, and in 2005 gained Tenure. In 2008, he was promoted to Professor. Dr. Schoenberger?s research focuses...
Sandrine Miller Montgomery, President & CEO,
Micronoma
Sandrine Miller-Montgomery, Pharm.D., Ph.D. is the co-founder, President and CEO of Micronoma, the first cancer-detection company using liquid biopsy technology to detect and predict cancer by analyzing the microbial signal with clinical-grade accuracy at an early stage of the disease. Prior to...
Dr Tyler Martin, Chairman, President & CEO,
Adjuvance Technologies
Prior to joining Adjuvance, Dr. Martin served as Chief Medical Officer, President and Director of Dynavax Technologies ( NASDAQ: DVAX ) where he oversaw clinical development of Heplisav and a TLR9 agonist 1018 . He served as President until 2013 when he left to pursue a position as founder and CEO ...
Mark Newman, CSO,
GeoVax, Inc.
Dr. Newman has more than 30 years’ experience in the biotechnology sector serving in senior management roles at GeoVax (Atlanta, GA), PaxVax (San Diego, CA), Pharmexa (Horsholm, Denmark), Epimmune (San Diego, CA), Vaxcel (Atlanta, GA), Apollon (Philadelphia, PA) and Cambridge Biotech (Boston, MA)...
Eric Ibsen, CEO & Co-Founder,
Studylog
Ibsen co-founded Studylog Systems in 2003 in response to what he saw as an unmet need in pre-clinical in vivo research for flexible, automated data collection and study management software. Ibsen has led Studylog to become the most-used application for drug discovery and efficacy research in the...
Tony Chen, President And Chief Executive Officer,
PrimeVax Immuno Oncology Inc
Tony is responsible for setting strategy and implementing the entirety of PrimeVax's clinical operations. Tony works closely with the PrimeVax Scientific Advisory Board to ensure that all strategies are supported by robust science and carried out correctly per oncology best practices.Tony’s...
Sandrine Miller Montgomery, President & CEO,
Micronoma
Sandrine Miller-Montgomery, Pharm.D., Ph.D. is the co-founder, President and CEO of Micronoma, the first cancer-detection company using liquid biopsy technology to detect and predict cancer by analyzing the microbial signal with clinical-grade accuracy at an early stage of the disease. Prior to...
William Smith, MD/PI,
Alliance for Multispecialty Research LLC
Dr. William Smith is the Founder, President, and Principal Investigator of VRG and NOCCR, the AMR centers in Knoxville, TN and New Orleans, LA. He is also one of the original founders of AMR. Dr. Smith is board certified in Internal Medicine, Critical Care Medicine, Nephrology and Cardiology. He...
Dr Nicholas Abuid, Field Application Scientist,
ACROBiosystems Inc.
Nicholas Abuid is the West Coat Field Application Scientist for Acro Biosystems. A biomedical engineer by training who focused on cell therapies for Type I Diabetes during his doctoral work. Nicholas is now working on recombinant proteins for CAR T cell therapies and COVID vaccine development. At...
Jason Devoss, Director,
Amgen
Jason is currently a Director in the Oncology Research Therapeutic Area at Amgen, Inc and located in the South San Francisco office. He earned a B.S. in Molecular and Cellular Biology from the University of Michigan in 1998. He then attended Stanford University where he completed graduate work...
Dr Carl Barrett, Vice President Of Translational Sciences,
AstraZeneca
Dr. J. Carl Barrett is Vice President & Global Head of Translational Medicine, Oncology R&D at AstraZeneca. He is responsible for development and execution of biomarker strategies and translational sciences efforts to support compound development from research through early and full...
Mohan Bolisetty, Associate Director,
Bristol-Myers Squibb
Mohan Bolisetty is the WW Medical Lead, Biomarkers in WW Medical Oncology. He is responsible for driving the solid tumor oncology biomarker strategy including ctDNA along with other genomics biomarkers. Prior to WWMO, Mohan was part of the Clinical Genetics and Genomics group within Translational...
Dr Diane Da Silva, Associate Director, Translational Medicine,
Parker Institute for Cancer Immunotherapy
Diane Da Silva, PhD, MS, is the Associate Director of Translational Medicine at the Parker Institute for Cancer Immunotherapy (PICI). She directs the execution of the PICI translational suite of biomarker assays and contributes to disease- and immune-specific biomarker approaches in collaboration...
Adam Simpson, Co-Founder And Chief Executive Officer,
Icosavax, Inc.
Adam Simpson is the chief executive officer (CEO) of Icosavax. He has substantial life science operational and emerging company experience and has executed significant partnering and acquisition transactions. Previously, Adam was CEO of PvP Biologics, another spinout from University of Washington’s ...
Kabeer Aziz, Co-Founder & Principal,
Adjuvant Capital
Kabeer co-founded Adjuvant Capital in 2018 to build an investment fund designed to accelerate the development of new technologies for the world’s most pressing public health challenges. Prior to Adjuvant, Kabeer was with the Global Health Investment Fund (GHIF) supporting companies focused on...
Joe Payne, Founder, President & Chief Executive Officer,
Arcturus Therapeutics
Mr. Joseph E. Payne founded Arcturus Therapeutics, Inc., in 2013 and serves as Chief Executive Officer and President. Mr. Payne served as the Chairman of the Board of Arcturus Therapeutics, Inc. and serves as its Director. He has an exceptional track record of ushering novel therapeutics to the...
Mark McDade, Managing Partner,
Qiming Venture Partners
Mark McDade co-founded Qiming Venture Partners USA in January 2017 and has over 30 years of successful operating experience in private and public healthcare and life sciences companies. Prior to Qiming, Mark was Executive Vice President and Chief Operating Officer (COO) of UCB, the...
Paul Robbins, Vice President, Translational Oncology,
Instil Bio
Paul B. Robbins Ph D. is a Senior Director at Pfizer and serves as the Global Translational Oncology Lead for development of Pfizer's avelumab/Bavencio (anti-PD-L1) program encompassing an array of immunotherapy combinations and accompanying diagnostics. He previously led the translational...
James Wassil, COO,
Vaxcyte
James Wassil, MBA, MS, is the Business Unit Lead at Pfizer Vaccineswith responsibilities of Health Outcomes, Cost-Effectiveness, Market Access, Tender Procurement and Pricing. James joined Pfizer in 2015 from Novartis, where he was Global Program Head for Meningococcal Vaccines and responsible...
Dr Jessica Baker Flechtner, Chief Scientific Officer,
Genocea Biosciences
Dr. Flechtner joined Genocea in 2007, soon after the company was founded, and currently serves as Chief Scientific Officer. She is widely recognized as a pioneer in the development of novel vaccines directed toward T cell immunity and has more than 20 years of experience in...
Karin Jooss, CSO,
Gritstone Oncology
Karin Jooss serves as Chief Scientific Officer of Gritstone Oncology. Dr. Jooss joined Gritstone from Pfizer, where she served as head of Cancer Immunotherapeutics within the Vaccine Immunotherapeutics department for seven years. While at Pfizer, she built and led immuno-oncology teams, was a...
Dr Ezra Cohen, Associate Director Of Moores Cancer Center,
U.C. San Diego Moores Cancer Center
Ezra Cohen, MD, is co-Director of the San Diego Center for Precision Immunotherapy and an internationally renowned translational researcher. He has been acknowledged for his contribution to the National Cancer Institute Task Force on PI3 Kinase/AKT/mTOR Targeting. A physician-scientist, Dr. Cohen...
Lance Baldo, Chief Medical Officer,
Adaptive Biotechnologies
Dr. Lance Baldo, MD, has served as Adaptive’s Chief Medical Officer since May 2019. From February 2010 to April 2019, Lance served in various roles of ascending responsibility with the Roche Group and its affiliates, including most recently as Senior Vice President and Head of U.S. Medical Affairs...
James Wassil, COO,
Vaxcyte
James Wassil, MBA, MS, is the Business Unit Lead at Pfizer Vaccineswith responsibilities of Health Outcomes, Cost-Effectiveness, Market Access, Tender Procurement and Pricing. James joined Pfizer in 2015 from Novartis, where he was Global Program Head for Meningococcal Vaccines and responsible...
Dr Todd Suscovich, Chief Technical Officer,
Seromyx
Dr. Todd Suscovich, Chief Technology Officer, leads the implementation and further development and of the Systems Serology platform at SeromYx, with a focus on expanding the use of this technology beyond the Infectious Disease space.Prior to joining SeromYx, his research broadly focused on how...
Prof. Wim Van Criekinge, Professor,
myNEO NV
Wim is one of the founders of Novalis Biotech Incubation. Wim is a professor in computational genomics and bioinformatics at Ghent University, and has strong track record for practical application of his expertise into innovative biotech business concepts. Wim Van Criekinge PhD is a tenured...
Alessandro Sette, Center Head, Division Head, And Professor,,
La Jolla Institute for Allergy and Immunology
Dr. Alessandro Sette has devoted more than 30 years to understanding and measuring immune responses, and developing disease intervention strategies against cancer, autoimmunity, allergy, and infectious diseases. Dr. Sette laboratory is focused on the study of the specific structures (epitopes) that ...
Rob Burgess, Chief Business Officer,
Sino Biological Inc
Dr. Burgess has 25 years of experience in the Life Sciences reagents and services industry. After obtaining his PhD from MD Anderson Cancer Center in 1995 he co-founded the gene targeting and drug discovery company Lexicon Pharmaceuticals and has since held other positions such as Director of...
Michael Humbert, Co-Founder & CTO,
NTx
Michael received his PhD in biochemistry from the University in Frankfurt/Main, Germany. He was a Research Fellow and Instructor at the Dana-Farber Cancer Institute and Harvard Medical School in Boston, MA, working on vaccine design and antibody development. In recent years, he developed diagnostic ...
David Anderson, Chief Scientific Officer,
VBI Vaccines
A dynamic and well-published immunologist with broad expertise in the areas of vaccine development, autoimmunity and tumor immunology, Dr. Anderson joined VBI full time in 2009 from Harvard Medical School, where he held a position as Assistant Professor. Dr. Anderson is an inventor of much of the...
Dr Heidi Trusheim, Head of Process Development,
IDT Biologika
Heidi Trusheim is Director of Process Development at IDT Biologika. As a scientist, Heidi has expertise in developing, overseeing, and validating processes to manufacture and commercialize novel biological products. Heidi received her PhD and MSc from the University of Osnabrück, Germany.
Brandon Lamarche, Principal Scientist, Head of xCELLigence Application Development,
Agilent
Brandon Lamarche received his Ph.D. in chemistry from Ohio State University. He subsequently worked as a postdoctoral fellow at the Salk Institute where he studied the biochemistry of DNA double strand break (DSB) repair in mammals, with particular focus on the type of DSBs generated by cancer...
Dr Erin Spiegel, VP Clinical & Regulatory Affairs,
Pharmajet
Dr. Erin Spiegel is the Director of Scientific Affairs at PharmaJet, a medical device company in Golden, Colorado, that has developed Needle-Free Injection technologies. Prior to joining PharmaJet, Erin worked as a Senior Regulatory Specialist at Evergreen Research and Scientific Consultant at CBR...
Dr. David Berd, Chief Medical Officer,
BioVaxys Technology Corp.
Dr. Berd is co-founder and Chief Medical Officer of Biovaxys Technology Corp. He is a medical oncologist with a lifelong record of clinical research in medical oncology and cancer immunotherapy. Previously, Dr. Berd was Professor of Medicine at Thomas Jefferson University, where for 20 years he...
Kevin Mccowen, Southwest Regional Manager,
Wyatt Technology Corporation
Kevin McCowen is the Southwest Regional Manager for Wyatt Technology. As a former bioanalytical chemist, Kevin spent 15 years working in various phases of pharmaceutical development and research before joining Wyatt as a Field Application Scientist. He is happy to be able to use his years of...
Tom Lake, SVP, Strategic Alliances & Commercialization,
Vaxxas
Tom Lake brings over 30 years of vaccine industry leadership in Manufacturing, Marketing and Sales with diverse, global experience at Merck Vaccines and GlaxoSmithKline Vaccines; Tom builds and supports new businesses that improve access to immunizations.
Daniel Henderson, CEO, CSO,
Verndari
Dr. Daniel Henderson is a co-founder and chief executive officer of Verndari, Inc., a clinical stage biopharmaceutical company based in Napa, California, that aims to transform global health through vaccine science.Prior to Verndari, Dr. Henderson co-founded and served as president of PaxVax, a...
Maria Karasarides, Vice-President, Head Early Assets & Biomarkers,
Bristol-Myers Squibb
Maria Karasarides, Ph.D. is an Executive Director, ImmunoOncology Development, at Regeneron Pharmaceuticals. Prior to joining Regeneron, Dr. Karasarides was a senior leader in the ImmunoOncology Late Stage Clinical Group at AstraZeneca where she oversaw the clinical strategy and scientific...
Robert Popovian, Senior Health Policy Fellow,
Progressive Policy Institute
Robert Popovian is currently Vice President, US Government Relations at Pfizer Inc. where he leads the advocacy function in the U.S. Robert brings over two decades of experience in numerous facets of biopharmaceutical and health care industry with a strong track record of expertise in Health Care...
Abby Bownas, Principal,
AVAC
Abby Bownas is a big thinker whose health background helps her deliver results on a range of “cradle-through-college-and-career” issues that ensure more people can lead happier, healthier lives. As NVG’s expert coalition builder, Abby manages the Adult Vaccine Access Coalition, bringing together...
Rekha Lakshmanan, Director, Advocacy And Policy,
The Immunization Partnership
Rekha Lakshmanan is a contributing expert for the Center for Health and Biosciences and director of policy at The Immunization Partnership (TIP) in Houston. Her work at TIP includes developing and implementing public policy strategies to improve Texas vaccination rates; advising other states and...
Kathryn Hashey, US Vaccine Policy Lead,
GSK
Accomplished researcher and public health advocate with 10+ years’ experience transecting R&D, project management and policy/government relations. Passionate about advancing scientific innovation and developing robust evidence-based policy solutions to improve public health. Currently, leading...
Denise Foster, COVID-19 Vaccine Clinical Director, Chief Nursing Officer, Medical Care Services,
County of San Diego Health and Human Services
Dr. Foster brings with her a wealth of experience in the art and science of healthcare management, including 20 years of progressive leadership in a variety of settings. In her current role as Chief Nursing Officer for the County of San Diego, Dr. Foster develops the strategic plan for nursing, and ...
Tim Soos, Director Immunology,
Codiak Biosciences
Timothy (Tim) Soos leads the Immunology Group at Codiak BioSciences where the team is focused on the preclinical development of exosome-based therapeutics and vaccines for oncology, autoimmunity and infectious diseases. Prior to Codiak, Tim was at Sanofi pharmaceuticals where he led the...
Martin Moore, Chief Executive Officer,
Meissa Vaccines, Inc
Martin (Marty) is a cofounder and chief executive officer of Meissa Vaccines. Prior to cofounding Meissa, Marty was an Associate Professor at Emory University and director of the Emory Children’s Center for Childhood Infections and Vaccines (CCIV). He developed an RSV reverse genetics platform...
Alexander Kort, SVP Corporate Development,
Themis Bioscience
Alexander Kort is SVP Corporate Development at Themis Bioscience GmbH in Vienna, Austria. His responsibilities include all business development and licensing activities of Themis and oversight of all internal corporate development activities. Alexander has more than 10 years' experience in the...
Mary Hauser, Senior Scientist,
GeoVax, Inc.
After obtaining a B.S. in Chemistry, Dr. Hauser received a Ph.D. in Microbiology & Immunology from Wake Forest University with a focus on the complex interplay of virus-host interactions. Dr. Hauser subsequently carried out postdoctoral research at University of Georgia and Virginia Tech...
